

Amendments to the Specification:

Page 1, before line 1, insert:

Cross Reference to Related Application

This application is a 35 USC § 371 National Phase Entry Application from PCT/EP2003/008205, filed July 25, 2003, and designating the U.S.

Please replace the last paragraph bridging pages 2 and 3 with the following amended paragraph.

The inhibition values are commonly indicated as IC_{50} (inhibitor concentration at 50% inhibition) and compared with each other. Low-molecular organic compounds according to the present invention refer to organic compounds with a relative molar mass ≤ 1000 , preferably ≤ 800 . Molecular-biological compounds according to the present invention refer to nucleic acids, in particular to RNA or DNA, which inhibit the expression of a component of the proteasomal system, e.g. the transcription or translation of the proteasome encoding nucleic acids, or to proteins, in particular binding peptides or binding proteins, these substances being directed against at least one component of the proteasomal system, preferably against ubiquitin and/or against the proteasome. Said nucleic acid e.g. is an anti-sense-RNA or a double-stranded RNA (dsRNA) against a proteasome encoding sequence, a ~~duplex~~ triplex forming oligonucleotide against a proteasome encoding sequence and/or a knock-out construct against a proteasome encoding sequence. Suitable as binding proteins or binding peptides e.g. are antibodies or their binding-reactive parts, e.g. single chain antibodies (scAb) or Fab-fragments or derivatives thereof, e.g. bi-specific antibodies against at least one component of the proteasomal system. A description of the proteasomal system and of suitable proteasome inhibitors is e.g. found in Kisselev A.F. & Goldberg A.L. (2001) Chemistry & Biology, 8, 739-758.